Literature DB >> 29326348

Choosing ibrutinib wisely.

Farrukh T Awan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29326348      PMCID: PMC5757683          DOI: 10.1182/blood-2017-11-813907

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.

Authors:  J Bertin; L Wang; Y Guo; M D Jacobson; J L Poyet; S M Srinivasula; S Merriam; P S DiStefano; E S Alnemri
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Authors:  Ajay K Gopal; Brad S Kahl; Christopher R Flowers; Peter Martin; Stephen M Ansell; Esteban Abella-Dominicis; Brian Koh; Wei Ye; Paul M Barr; Gilles A Salles; Jonathan W Friedberg
Journal:  Blood       Date:  2017-03-21       Impact factor: 22.113

3.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

4.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

5.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Authors:  Alessandro Pastore; Vindi Jurinovic; Robert Kridel; Eva Hoster; Annette M Staiger; Monika Szczepanowski; Christiane Pott; Nadja Kopp; Mark Murakami; Heike Horn; Ellen Leich; Alden A Moccia; Anja Mottok; Ashwini Sunkavalli; Paul Van Hummelen; Matthew Ducar; Daisuke Ennishi; Hennady P Shulha; Christoffer Hother; Joseph M Connors; Laurie H Sehn; Martin Dreyling; Donna Neuberg; Peter Möller; Alfred C Feller; Martin L Hansmann; Harald Stein; Andreas Rosenwald; German Ott; Wolfram Klapper; Michael Unterhalt; Wolfgang Hiddemann; Randy D Gascoyne; David M Weinstock; Oliver Weigert
Journal:  Lancet Oncol       Date:  2015-08-06       Impact factor: 41.316

6.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

7.  Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

Authors:  Nancy L Bartlett; Brian A Costello; Betsy R LaPlant; Stephen M Ansell; John G Kuruvilla; Craig B Reeder; Lim S Thye; Daniel M Anderson; Kilannin Krysiak; Cody Ramirez; Jing Qi; Barry A Siegel; Malachi Griffith; Obi L Griffith; Felicia Gomez; Todd A Fehniger
Journal:  Blood       Date:  2017-10-26       Impact factor: 25.476

8.  Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

Authors:  M Dreyling; F Morschhauser; K Bouabdallah; D Bron; D Cunningham; S E Assouline; G Verhoef; K Linton; C Thieblemont; U Vitolo; F Hiemeyer; M Giurescu; J Garcia-Vargas; I Gorbatchevsky; L Liu; K Koechert; C Peña; M Neves; B H Childs; P L Zinzani
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.